MBRX Stock Ownership Breakdown

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own MBRX shares is 19, representing 15.34% of the company's common stock.

BLACKROCK INC., in the last quarter, reduced its stake in MBRX by -3.76% restricting it's holding to 188.92 thousand shares of worth nearly $162.17K. SIGMA PLANNING CORP also lessened -29.41% of the MBRX shares from its portfolio, reducing its holding to 12 thousand shares of worth $10.30K. TOWER RESEARCH CAPITAL LLC (TRC) also shunned MBRX shares holding by -49.66% last quarter which brought its holding to 7.2 thousand shares worth $6.18K.

As per its latest 13F filing, ARMISTICE CAPITAL, LLC increased its stake in MBRX by 100% in the last quarter. The institutional holder raised its holding to 3.21 million shares having worth more than $2.75M. BANK OF AMERICA CORP /DE/ also added 38% more shares of MBRX to its portfolio, raising its holding to 138 shares of worth $118.00. RENAISSANCE TECHNOLOGIES LLC also increased its MBRX shares holding by 7.82% which brought its holding to 129.6 thousand shares worth $111.00K.

The insider with the most stakes in MBRX is CREDIT SUISSE/ , 10 percent owner at the company. Additionally, MBRX stock is highly held by 10 percent owner Priebe Waldemar and CEO and President KLEMP WALTER V among others.

Company executives, directors, and other insiders own 3.34% percent of Moleculin Biotech, Inc.'s stock. Within the last six months, there have been 0 transaction(s) in which MBRX insiders have sold stock, totaling 0 shares. Insiders that have sold shares include PRIEBE WALDEMAR, KLEMP WALTER V, and BARACCHINI EDGARDO JR.

There have been 0 transaction(s) during the past 6-months in which Moleculin Biotech, Inc. insiders have bought stock, totalling 0 shares

Around 0 Moleculin Biotech, Inc. shares are held by insiders, which represents about 3.34% of MBRX stock.

MBRX 10 percent owner, CREDIT SUISSE/ holds the largest portfolio of the company's shares. MBRX shares owned by CREDIT total nearly 3.86 million.

ARMISTICE CAPITAL, LLC is the largest institutional owner in MBRX which holds 3.21 million shares worth $2.75M or 10.76% of the total MBRX shares outstanding followed by VANGUARD GROUP INC with ownership of 1.08 million shares representing 3.62% of the MBRX ownership. BANK OF AMERICA CORP /DE/ is the third largest stakeholder with 138 shares or 0% of the ownership worth more than $118.00.

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the MBRX is concerned, it is a stock which is not optionable.

Number of MBRX shares short is 82.13K. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

As of today, 3.19M shares of MBRX are outstanding.

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, MBRX has 2.73M shares in float.

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for MBRX is 1.23.